Table of Contents
ISRN Urology
Volume 2012, Article ID 762340, 4 pages
Clinical Study

Fournier's Gangrene: Conventional Dressings versus Dressings with Dakin's Solution

1Department of Urology, Medical Faculty, Kahramanmaraş Sütçü İmam University, Yörükselim Mah. Hastane Cad. No. 32, 46100 Kahramanmaraş, Turkey
2Department of Urology, Kahramanmaras State Hospital, 46100 Kahramanmaraş, Turkey
3Private Kadirli 7 Mart Hospital, 46100 Osmaniye, Turkey
4Department of Plastic Surgery, Medical Faculty, Kahramanmaraş Sütçü İmam University, 46100 Kahramanmaraş, Turkey

Received 3 November 2011; Accepted 15 December 2011

Academic Editor: K. Naber

Copyright © 2012 Bülent Altunoluk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. Fournier’s gangrene is a fulminant and destructive inflammation of the scrotum, penis, and perineum. The objective of this study was to compare 2 different approaches to wound management after aggressive surgical debridement. Methods. Data from 14 patients with Fournier’s gangrene were retrospectively collected (2005–2011). Once the patients were stabilized following surgery, they were treated with either daily antiseptic (povidone iodine) dressings (group I, 𝑛 = 6 ) or dressings with dakin’s solution (sodium hypochloride) (group II, 𝑛 = 8 ). Results. The mean age of the patients was 68.2 ± 7.8 (55–75) years in group I and 66.9 ± 10.2 (51–79) years in group II. Length of hospital stay was 13 ± 3.5 (7–16) days in group I and 8.9 ± 3.0 (4–12) days in group II ( 𝑃 < 0 . 0 5 ). The number and rate of mortality was 1/6 (16.7%) in group I, and 1/8 (12.5%) in group II. Conclusions. The hospitalization time can be reduced with the use of dakin’s solution for the dressings in the treatment of FG. Also, dressings with dakin’s solution seems to have favorable effects on morbidity and mortality. Consequently dakin’s solution may alter the treatment of this disastrous disease by reducing cost, morbidity and mortality.